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1. Introduction 
Met- and Leu-enkephalin first isolated from pig 
brain as endogenous ligands for opioid receptors [1 ], 
have later been shown to occur also in peripheral ner- 
vous tissue such as the plexus of the gastrointestinal 
tract of some species [2] and the bovine adrenal 
medulla [3,4]. Peptides probably identical with Met- 
and Leu-enkephalin are also present in neuroblas- 
toma X glioma hybrid cells 108CC15, as determined 
by 3 independent assays [5,6]. These hybrid cells 
express many properties characteristic of neurons. 
One is their production of acetylcholine, another 
their response to several neurohormones. The eleva- 
tion by prostaglandin E1 (PGEx) of the intracellular 
concentration f adenosine 3',5'-cyclic monophos- 
phate (cyclic AMP) is inhibited by opioids. The inhi- 
bition is prevented by the opioid antagonist naloxone 
(review [7]). 
Little is known about he regulatory mechanisms, 
which control the neuronal concentration f the 
enkephalins [8-12]. Here we report hat in the 
hybrid cells 108CC 15 glucocorticoids specifically 
increase the intracellular concentration f opioid 
peptides. 
2. Materials and methods 
Dexamethasone (Dex), progesterone, corticoste- 
rone and testosterone were from Sigma (Mtinchen); 
aldosterone from Serva (Heidelberg); diazepam from 
Hoffman-La Roche (Grenzach); naloxone from Endo- 
Labs. (Garden City NY). PGE1 from Upjohn Co. 
(Kalamazoo MI); Leu- and Met-enkephalin (Leu- and 
Met-Enk) were gifts from Drs L. Moroder and E. 
Wiinsch (Martinsried); [all] Leu-enkephalin (64 Ci/ 
mmol) and [all] Met-enkephalin (36 Ci/mmol)were 
purchased from Amersham Buchler (Braunschweig). 
Culturing of cells in Petri dishes (145 mm diam.) 
and multiwell trays containing 24 wells (16 mm 
diam.), as well as the preparation and purification of 
extracts have been described [5,6]. Briefly, cells were 
extracted by 1 M acetic acid. After addition of 
6.5 × 104 dpm of [aH] Leu-Enk, and sometimes also 
of [aH]Met-Enk, for determination f the recovery, 
the extracts were purified by adsorption chromatog- 
raphy on polystyrene beads and subsequent chroma- 
tography on Sephadex LH-20 [6]. These extracts, 
finally dissolved in 200/al 0.05 M Tris-HC1, pH 7.4 
(25°C) will be referred to as partially purified extracts. 
In some instances partially purified extracts were 
further purified by high performance liquid chroma- 
tography (HPLC) [6]. Briefly, partially purified 
extracts were isocratically chromatographed on an 
analytical C18-reversed-phase column at a flow rate of 
1.5 ml/min. The solvent system was 59% 0.001 M 
ammonium acetate (pH 4.5) and 41% methanol. Frac- 
tions were collected according to a calibration of the 
column with synthetic Met- and Leu-Enk. Evaporated 
fractions were dissolved in 200 btl 0.05 M Tris-HC1, 
pH 7.4 (25°C). Hormones were added to the growth 
medium as 50/aM solutions in Dulbecco's modified 
Eagle's medium and, unless indicated otherwise, were 
present during the whole culture period. 
Opioid activity in the extracts was determined by 
2 independent assays: 
(i) A radioimmunoassay with an antiserum against 
Leu-Enk was performed by a standard procedure 
[5,13]. The antiserum was specific for the two 
enkephalins; none of the many other peptides 
tested, including the endorphins, crossreacted 
[13,14]. 
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(ii) Hybrid cells were incubated (10 min, 37°C) with 
PGE1 and Leu-Enk or extract fractions before 
the concentration f cyclic AMP was determined 
as in [14,15]. 
In the protein assay [16] bovine serum albumin 
was used as a standard. 
3. Results 
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In hybrid cell extracts, opioid activity is equally 
enhanced (3-4-fold) after incubation of the cells 
with Dex and corticosterone (table 1). But in most 
other experiments corticosterone was somewhat less 
potent han Dex. The stimulation over the control by 
Dex varies mostly between 3-5-fold. The effect is 
specific for glucocorticoids. Of the other steroid 
hormones tested only aldosterone exerts a small stim- 
ulatory effect. Sometimes opioid activity is detected 
in C6-BU-1 glioma cells [6]. However, this activity 
cannot be increased by treatment with Dex (not 
shown). 
Half-maximal elevation of opioid activity in hybrid 
cells is achieved at 50 nM (fig.l). At higher concen- 
trations the intracellular level of opioids decreases 
again. The maximal cellular content of opioids is gen- 
erally obtained already after a 1 day incubation with 
Dex (fig.2). Only occasionally, a somewhat longer 
period (1 .5-2 days) is necessary. The initial decrease 
of opioid activity after 6 h incubation isunexplained. 
Dex increases the content in the hybrid cells of Met- 
and Leu-Enk-like material (fig.3). In order to demon- 
strate this, partially purified extracts were further 
Table 1 
Effect of several steroid hormones and dexamethasone on the 
opioid activity of hybrid cells 
Addition to the Protein/dish Leu-Enk-equiv. 
growth medium (1 uM) (mg) (pmol/mg protein) 
- 6.8 0.05 
Dexamethasone 6.9 0.18 
Corticosterone 8.2 0.17 
Aldosterone 7.2 0.10 
Testosterone 8.6 0.04 
Progesterone 7.4 0.05 
After a culture period of 4 days each extract was prepared 
from cells (passage no. 20 = P 20) of 12-14 Petri dishes. All 
extracts were partially purified. Opioid activity was deter- 
mined by radioimmunoassay 
-- log ( [dexamethasone] (mol  I 1 )) 
Fig.1. Effect of the concentration f Dex on the level of 
opioids in hybrid cells. Each of the partially purified extracts 
was prepared from cells (P 20) of 11-15 Petri dishes. Their 
content of opioids was determined by radioimmunoassay. 
purified by HPLC. The fractions with the retention 
times of Met- and Leu-Enk were assayed for their 
capacity to inhibit the PGErevoked increase in the 
level of cyclic AMP. For comparison, the inhibitory 
action of Leu-Enk is shown in fig.3A (curve a). The 
Met-Enk-like (fig.3B,D, curves a) and the Leu-Enk- 
like fractions (fig.3C,E, curves a) also inhibit the 
formation of cyclic AMP. After treatment of hybrid 
cells with Dex, lower volumes of both the Met- and 
Leu-Enk-like fractions (fig.3D,E, curves a) are neces- 
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Fig.2. Time course of the Dexqnduced increase in the con- 
centration ofopioids in hybrid cells. At the indicated times 
before extraction of the cells (P 18) 1.2 ml of a 50 ~M solu- 
tion of Dex was added to a number (10-14) of Petri dishes 
idled with 60 ml growth medium (final conc. 1 uM). At the 
time of extraction the cellular protein content/Petri dish was 
5-6 mg. The extracts were partially purified. Their content 
of opioids was determined by radioimmunoassay. 
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Fig.3. Leu-Enk (A) and HPLC-fractions of extracts of hybrid cells that had been cultured in the absence (B,C) or presence (D,E) 
of Dex, inhibit he PGEl-elicited formation of cyclic AMP in hybrid cells. The assays were carried out in the absence (curves a) or 
presence (curves b) of 10 ~M naloxone: 2.2 X 105 viable cells/well, 16 mm diam., 96% viability, passage no. 17. PGE 1 was 0.3 #M. 
Each value is the mean ± SD of data obtained from two parallel incubations. Each extract was prepared from cells of 30 Petri 
dishes, each containing 6.0-7.0 mg cellular protein. Cells were cultured for 4 days in the presence of 1 gM Dex. Final volume of 
the fractions was 200 ~1: Leu-Enk (A); Met-Enk-like fraction (B,D); Leu-Enk-like fraction (C,E). The recoveries after the purifica- 
tin o f the extracts were: for [ 3H] Met-Enk 25% (B) and 20% (D); for [ a H] Leu-Enk 34% (C) and 28% (E). 
sary to cause the same inhibition as in the controls 
(fig.3B,C, curves a). This indicates, that after treat- 
ment with Dex both fractions contain an elevated 
amount of opioids. The effects of all fractions and of 
synthetic Leu-Enk are prevented by the opioid antag- 
onist naloxone (fig.3, curves b). The ratio in the 
hybrid cell extracts of Met- to Leu-Enk-like peptide 
of 3-4:1  is unaltered by treatment with Dex. 
The neurohormones acetylcholine and opioid pep- 
tides released by the hybrids might regulate via the mus- 
carinic [ 18] and opioid receptors, respectively, the 
content of opioids in these cells. However, the level 
of opioid peptides in the hybrids is neither affected 
by the agonists carbachol and morphine nor by the 
antagonists atropine and naloxone. Also diazepam is
without effect (not shown). 
4. Discussion 
Adrenalectomy leads to an increase in the concen- 
tration of/3-endorphin i  the anterior lobe of the 
pituitary gland [10]. In congruence herewith is the 
decrease caused by dexamethasone i  the intracellular 
concentration f/3-endorphin i  vitro in cultured 
pituitary tumor cells AtT-20 [19] and in vivo in the 
anterior lobe [10]. In contrast, after large doses of 
Dex levels of enkephalin were slightly increased in rat 
striatum [10]. In accord with this report is our find- 
ing with the aid of two different assays that exposure 
of neuroblastoma × glioma hybrid cells to Dex raises 
the intracellular level of enkephalin-like p ptides. 
With 3-5-fold this stimulation ismuch more pro- 
nounced than in the in vivo experiments [10]. This 
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difference may be due to different concentrations of
glucocorticoids in brain and in the culture medium. 
The latter contains fetal calf serum necessary for the 
growth of the hybrids. On the other hand, adrenal- 
ectomy does not influence enkephalin levels in brain 
[ 10]. In view of these results, the hybrid cells appear 
to be a useful model for studying the regulation of 
enkephalin-like peptides by glucocorticoids. This 
study and the fact that the hybrid cells do not con- 
tain endorphins indicates that the enkephalin and the 
endorphin systems are different. 
Of the steroid hormones tested, only the corti- 
coids alter the level of opioids in the hybrids, the 
maximal effect being observed at 1/2M Dex and after 
an incubation of at least 1 day. Similar specificity and 
optimal conditions have been reported for the action 
of glucocorticoids in other systems [20-23],  e.g., the 
induction of glutamine synthetase in primary brain 
cell cultures [20]. The equal increase by glucocorti- 
coids in the concentrations of the Met- and Leu-Enk- 
like peptides may be explained by the induction of a 
common precursor protein, such as has been isolated 
recently from bovine adrenal medulla [24]. It is not 
known whether the increase in the level of enkephalin- 
like material is due to enhanced synthesis or to 
decreased egradation or release. However, the latter 
is unlikely, since hydrocortisone inhibits the release 
of prostaglandins from fat cells already within minutes 
[25]. On the other hand, it is conceivable that the 
enzymes presumably involved in the processing of the 
precursor molecule are regulated by glucocorticoids. 
The decrease at >1/IM Dex in the dose-response 
curve (fig.l) may be explained in at least two ways: 
(i) Dex may perturbe membranes and thus cause an 
enhanced release of opioids; 
(ii) Dex may exert a cytotoxic effect, as has been 
observed for the induction of tyrosine hydroxyl- 
ase in rat pheochromocytoma cells [ 17]. In 
accord herewith would be the reduction by 35% 
in protein content per dish, noticed at 50 laM 
Dex (fig.l). 
As to the cell type, the elevation by glucocorti- 
colds of  opioid levels in hybrid ceils appears to be 
somewhat specific. We observed no such regulation of 
opioid levels in glioma cells, although it is demon- 
strated by the induction of glutamine synthetase 
[20,21 ] that these cells are indeed susceptible to 
glucocorticoids. 
The level of opioids is not altered via the muscarinic 
cholinergic or the opioid receptors present on the 
hybrid cells. Agonists or antagonists for both recep- 
tors are without clearcut reproducible ffects. This is 
in contrast o the adrenal medulla where acetylcho- 
line causes via a nicotinic cholinergic receptor [26] a 
significant release of opioid peptides from the chro- 
maffin cells [4]. This difference may be due to differ- 
ences in the state of differentiation or the cholinergic 
receptors involved. Hybrid cells become differenti- 
ated and electrically excitable after treatment with 
dibutyryl adenosine 3': 5'-cyclic AMP. It remains to 
be elucidated whether or not under such conditions 
acetylcholine causes an increased release of opioids 
from hybrid cells. In contrast o the rat brain [9], in 
hybrid cells diazepam causes no alteration in the level 
of opioid peptides. It is not known whether the lack 
of effect of diazepam on the level of cyclic AMP in 
the hybrids [27] is of any significance in this context. 
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